<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00663000</url>
  </required_header>
  <id_info>
    <org_study_id>T-7538</org_study_id>
    <secondary_id>T-7538</secondary_id>
    <nct_id>NCT00663000</nct_id>
  </id_info>
  <brief_title>Glucose Tolerance in Acromegaly: The Influence of GH-excess on Glucose Metabolism and Insulin Resistance</brief_title>
  <official_title>Observational, Cross-sectional, Longitudinal, Multi-center, Diagnostic Study to Evaluate the Influence of Acromegaly on Glucose Tolerance and to Evaluate the Changes of Impaired Glucose Tolerance During Standard Treatment of Acromegaly.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational, Cross-sectional, longitudinal, multi-center, diagnostic study

      Cross-sectional part of the study: To evaluate the influence of acromegaly on glucose
      tolerance

      Longitudinal part of the study: To evaluate the changes of impaired glucose tolerance during
      standard treatment of acromegaly. Adult patients with established acromegaly

      Cross-sectional part of the study: 150 patients

      Longitudinal part of the study: 58 patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TRIAL DESIGN Observational, cross-sectional (patients with normal glucose tolerance).
      longitudinal (patients with impaired glucose tolerance), multi-center, diagnostic study.

      After checking the inclusion and exclusion criteria for the cross-sectional part of the study
      patients will be included for anamnesis according to Flow Chart Visit -1 (Screening Visit).
      After checking the glucose tolerance and the insulin resistance by HOMA-IR, the patients will
      be classified to the group with normal glucose tolerance defined as:

        -  fasting plasma glucose &lt; 110 mg/dl and/or 2-hour plasma glucose after an OGTT &lt; 140
           mg/dl or to the group with impaired glucose tolerance defined as:

             -  fasting plasma glucose ≥ 110 mg/dl (IFG) and/or 2-hour plasma glucose after an OGTT
                ≥ 140 mg/dl (IGT). For the HOMA-IR the cut off is 1.5.

      For patients with normal glucose tolerance the study will end after Screening Visit (V -1).

      After patient recruitment of the cross-sectional part is completed an interim analysis is
      planned to verify that all criteria for the longitudinal study part are achieved. The
      longitudinal part should start not later than one year after the last patient was examined in
      the cross-sectional part. For patients with impaired glucose tolerance the inclusion and
      exclusion criteria for the longitudinal part of the study will be checked (Baseline, Visit
      0). If a patient might be included into the longitudinal part of the study a 12 months
      observation with 4 further visits will follow.

      Primary Objective and Endpoint

      Cross-sectional part of the study:

      To evaluate a correlation between IGF-I and glucose tolerance in acromegalic patients. The
      inclusion should be performed in 2 stratification groups.

      Following two groups are defined:

        1. 1/3 of patients with a controlled IGF-I (controlled means IGF-I in age and sex-related
           normal reference range.

        2. 2/3 of patients with an uncontrolled IGF-I (uncontrolled means IGF-I not in age and sex
           related normal reference range.

      Longitudinal part of the study:

      To evaluate changes of impaired glucose tolerance by different standard treatment options in
      acromegaly.

      For the analysis of the different treatment options patients will be stratified into 5
      treatment groups. Decision will be made according to next planned therapeutic intervention at
      Screening Visit (V -1):

        1. Surgery

        2. Treatment with somatostatin analoga (with or without combination of dopamine agonists)

        3. Treatment with growth hormone receptor antagonist

        4. Treatment with somatostatin analoga in combination with growth hormone receptor
           antagonist

        5. Others (e.g. radiation, dopamine agonist monotherapy, no intervention)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate a correlation between IGF-I and glucose tolerance in patients with acromegaly.To evaluate changes of impaired glucose tolerance by different treatment options for acromegaly.</measure>
    <time_frame>cross-sectional; 1 year longitudinal</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate a correlation between body weight/BMI, age, family history of diabetes,duration of acromegaly and current medical treatment for acromegaly and glucose tolerance / insulin resistance</measure>
    <time_frame>cross-sectional, 1 year longitudinal</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">138</enrollment>
  <condition>Acromegaly</condition>
  <condition>Diabetes</condition>
  <condition>Insulin Resistance</condition>
  <condition>Impaired Glucose Tolerance</condition>
  <arm_group>
    <arm_group_label>acromegalics</arm_group_label>
    <description>Acromegaly in adult subjects either controlled or uncontrolled (Diagnosis should be based on OGTT where Acromegaly is defined as a lack of suppression of GH nadir to &lt; 0.5 ng/dL, after oral administration of 75 g of glucose, OGTT and IGF-I levels at least 10 % above the normal value ± 2 SD).
Written informed consent</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. Acromegaly in adult subjects (≥ 18 years) either controlled or uncontrolled (Diagnosis
             should be based on OGTT where Acromegaly is defined as a lack of suppression of GH
             nadir to &lt; 0.5 ng/dL, after oral administration of 75 g of glucose, OGTT and IGF-I
             levels at least 10 % above the normal value ± 2 SD).

          2. Written informed consent
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Acromegaly in adult subjects (≥ 18 years) either controlled or uncontrolled (Diagnosis
             should be based on OGTT where Acromegaly is defined as a lack of suppression of GH
             nadir to &lt; 0.5 ng/dL, after oral administration of 75 g of glucose, OGTT and IGF-I
             levels at least 10 % above the normal value ± 2 SD).

          2. Written informed consent

        Exclusion Criteria:

          1. Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent
             hepatitis, or persistent ALT, AST, alkaline phosphatase 3 x &gt; upper limit of normal,
             or total bilirubin 2 x &gt; upper limit of normal.

          2. Renal failure (GFR ≤ 30 ml/min)

          3. Abnormal clinical laboratory values considered by the investigator to be clinically
             significant and which could affect the interpretation of the study results.

          4. History of malignancy of any organ system, treated or untreated, within the past 3
             years whether or not there is evidence of local recurrence or metastases, with the
             exception of localized basal cell carcinoma of the skin.

          5. Suspected or known drug or alcohol abuse.

          6. Any condition which in the opinion of the investigator makes the patient unsuitable
             for inclusion.

          7. Participation in any other clinical trial with an investigational new drug.

          8. Patients on longterm, continuous (more than 2 weeks/year) systemic therapy with
             glucocorticosteroids with exception of a substitution of a pituitary lack of
             ACTH/cortisol (e.g. patients with panhypopituitarism).

          9. Instable heart insufficiency for example cardiomyopathy, congestive heart failure
             (NYHA class III or IV), unstable angina, sustained ventricular tachycardia,
             ventricular fibrillation).

         10. Type I diabetes according to the guidelines of the European Diabetes Society or
             obvious other manifestations of other forms of diabetes (e.g. steroid diabetes).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baptist Gallwitz, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. Medicine IV. Tuebingen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. Internal Medicine, Div. Endocrinology, Charité Campus Mitte, University of Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endokrinologikum Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. Internal Medicine, Div. Endocrinology, University of Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. Internal Medicine, Endocrinology, Max Planck Institute for Neuroscience and Psychiatry</name>
      <address>
        <city>München</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische/Endokrinologische Praxis Dr. Droste</name>
      <address>
        <city>Oldenburg</city>
        <zip>26122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. Medicine IV</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab. 1998 Oct;83(10):3411-8.</citation>
    <PMID>9768640</PMID>
  </reference>
  <reference>
    <citation>Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998 Feb;83(2):374-8.</citation>
    <PMID>9467544</PMID>
  </reference>
  <reference>
    <citation>Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB, Wass JA. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf). 1999 May;50(5):561-7.</citation>
    <PMID>10468920</PMID>
  </reference>
  <reference>
    <citation>Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, Sandler HM. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab. 1997 Oct;82(10):3187-91.</citation>
    <PMID>9329336</PMID>
  </reference>
  <reference>
    <citation>Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med. 1993 May;86(5):293-9.</citation>
    <PMID>8327647</PMID>
  </reference>
  <reference>
    <citation>Biermasz NR, van Dulken H, Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab. 2000 Jul;85(7):2476-82.</citation>
    <PMID>10902796</PMID>
  </reference>
  <reference>
    <citation>Caron P, Tabarin A, Cogne M, Chanson P, Jaquet P. Variable growth hormone profiles following withdrawal of long-term 30mg slow-release lanreotide treatment in acromegalic patients: clinical implications. Eur J Endocrinol. 2000 Jun;142(6):565-71.</citation>
    <PMID>10822218</PMID>
  </reference>
  <reference>
    <citation>Clemmons DR. Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly. Pituitary. 2002;5(3):181-3. Review.</citation>
    <PMID>12812310</PMID>
  </reference>
  <reference>
    <citation>Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol. 2006 Mar;154(3):467-77.</citation>
    <PMID>16498061</PMID>
  </reference>
  <reference>
    <citation>Davies PH, Stewart SE, Lancranjan L, Sheppard MC, Stewart PM. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf). 1998 Mar;48(3):311-6. Erratum in: Clin Endocrinol (Oxf) 1998 May;48(5):673.</citation>
    <PMID>9578821</PMID>
  </reference>
  <reference>
    <citation>Eastman RC, Gorden P, Glatstein E, Roth J. Radiation therapy of acromegaly. Endocrinol Metab Clin North Am. 1992 Sep;21(3):693-712. Review.</citation>
    <PMID>1521519</PMID>
  </reference>
  <reference>
    <citation>Elmlinger MW, Kühnel W, Weber MM, Ranke MB. Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med. 2004;42(6):654-64.</citation>
    <PMID>15259383</PMID>
  </reference>
  <reference>
    <citation>Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore). 1994 Sep;73(5):233-40.</citation>
    <PMID>7934807</PMID>
  </reference>
  <reference>
    <citation>Fahlbusch R, Honegger J, Buchfelder M. Evidence supporting surgery as treatment of choice for acromegaly. J Endocrinol. 1997 Oct;155 Suppl 1:S53-5.</citation>
    <PMID>9389996</PMID>
  </reference>
  <reference>
    <citation>Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, van der Lely AJ. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet. 2005 May 7-13;365(9471):1644-6. Erratum in: Lancet. 2005 May;365(9471):1620.</citation>
    <PMID>15885297</PMID>
  </reference>
  <reference>
    <citation>Feenstra J, van Aken MO, de Herder WW, Feelders RA, van der Lely AJ. Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. Eur J Endocrinol. 2006 Jun;154(6):805-6.</citation>
    <PMID>16728538</PMID>
  </reference>
  <reference>
    <citation>Fløgstad AK, Halse J, Bakke S, Lancranjan I, Marbach P, Bruns C, Jervell J. Sandostatin LAR in acromegalic patients: long-term treatment. J Clin Endocrinol Metab. 1997 Jan;82(1):23-8.</citation>
    <PMID>8989226</PMID>
  </reference>
  <reference>
    <citation>Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000 Feb;85(2):526-9. Review.</citation>
    <PMID>10690849</PMID>
  </reference>
  <reference>
    <citation>Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M, Rizza R. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am J Physiol. 1986 Mar;250(3 Pt 1):E269-73.</citation>
    <PMID>3513613</PMID>
  </reference>
  <reference>
    <citation>Hunter SJ, Shaw JA, Lee KO, Wood PJ, Atkinson AB, Bevan JS. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion. Clin Endocrinol (Oxf). 1999 Feb;50(2):245-51.</citation>
    <PMID>10396369</PMID>
  </reference>
  <reference>
    <citation>Jaffe CA, Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am. 1992 Sep;21(3):713-35. Review.</citation>
    <PMID>1355728</PMID>
  </reference>
  <reference>
    <citation>Jørgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LØ, Hagen C, Ørskov H. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab. 2005 Oct;90(10):5627-31. Epub 2005 Jul 26.</citation>
    <PMID>16046586</PMID>
  </reference>
  <reference>
    <citation>Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul;28(7):412-9.</citation>
    <PMID>3899825</PMID>
  </reference>
  <reference>
    <citation>Melmed S. Acromegaly. N Engl J Med. 1990 Apr 5;322(14):966-77. Review.</citation>
    <PMID>2179724</PMID>
  </reference>
  <reference>
    <citation>Møller N, Schmitz O, Jøorgensen JO, Astrup J, Bak JF, Christensen SE, Alberti KG, Weeke J. Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J Clin Endocrinol Metab. 1992 May;74(5):1012-9.</citation>
    <PMID>1569148</PMID>
  </reference>
  <reference>
    <citation>Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab. 1998 Aug;83(8):2730-4.</citation>
    <PMID>9709939</PMID>
  </reference>
  <reference>
    <citation>Osman IA, James RA, Chatterjee S, Mathias D, Kendall-Taylor P. Factors determining the long-term outcome of surgery for acromegaly. QJM. 1994 Oct;87(10):617-23.</citation>
    <PMID>7987657</PMID>
  </reference>
  <reference>
    <citation>Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf). 1994 Jul;41(1):95-102.</citation>
    <PMID>8050136</PMID>
  </reference>
  <reference>
    <citation>Rose DR, Clemmons DR. Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm IGF Res. 2002 Dec;12(6):418-24.</citation>
    <PMID>12423627</PMID>
  </reference>
  <reference>
    <citation>Saccà L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev. 1994 Oct;15(5):555-73. Review.</citation>
    <PMID>7843068</PMID>
  </reference>
  <reference>
    <citation>Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ; German Pegvisomant Investigators. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol. 2007 Jan;156(1):75-82.</citation>
    <PMID>17218728</PMID>
  </reference>
  <reference>
    <citation>Stumvoll M, Van Haeften T, Fritsche A, Gerich J. Oral glucose tolerance test indexes for insulin sensitivity and secretion based on various availabilities of sampling times. Diabetes Care. 2001 Apr;24(4):796-7.</citation>
    <PMID>11315860</PMID>
  </reference>
  <reference>
    <citation>Sze L, Schmid C, Bloch KE, Bernays R, Brändle M. Effect of transsphenoidal surgery on sleep apnoea in acromegaly. Eur J Endocrinol. 2007 Mar;156(3):321-9.</citation>
    <PMID>17322492</PMID>
  </reference>
  <reference>
    <citation>Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998 Oct;83(10):3419-26.</citation>
    <PMID>9768641</PMID>
  </reference>
  <reference>
    <citation>Tindall GT, Oyesiku NM, Watts NB, Clark RV, Christy JH, Adams DA. Transsphenoidal adenomectomy for growth hormone-secreting pituitary adenomas in acromegaly: outcome analysis and determinants of failure. J Neurosurg. 1993 Feb;78(2):205-15.</citation>
    <PMID>8421204</PMID>
  </reference>
  <reference>
    <citation>van der Lely AJ, de Herder WW, Lamberts SW. A risk-benefit assessment of octreotide in the treatment of acromegaly. Drug Saf. 1997 Nov;17(5):317-24. Review.</citation>
    <PMID>9391775</PMID>
  </reference>
  <reference>
    <citation>van der Lely AJ, Muller A, Janssen JA, Davis RJ, Zib KA, Scarlett JA, Lamberts SW. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab. 2001 Feb;86(2):478-81.</citation>
    <PMID>11157994</PMID>
  </reference>
  <reference>
    <citation>Veysey MJ, Thomas LA, Mallet AI, Jenkins PJ, Besser GM, Wass JA, Murphy GM, Dowling RH. Prolonged large bowel transit increases serum deoxycholic acid: a risk factor for octreotide induced gallstones. Gut. 1999 May;44(5):675-81.</citation>
    <PMID>10205204</PMID>
  </reference>
  <reference>
    <citation>Wasada T, Aoki K, Sato A, Katsumori K, Muto K, Tomonaga O, Yokoyama H, Iwasaki N, Babazono T, Takahashi C, Iwamoto Y, Omori Y, Hizuka N. Assessment of insulin resistance in acromegaly associated with diabetes mellitus before and after transsphenoidal adenomectomy. Endocr J. 1997 Aug;44(4):617-20.</citation>
    <PMID>9447299</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2008</study_first_submitted>
  <study_first_submitted_qc>April 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2008</study_first_posted>
  <last_update_submitted>September 13, 2014</last_update_submitted>
  <last_update_submitted_qc>September 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Baptist Gallwitz</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>acromegaly</keyword>
  <keyword>diabetes</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>impaired glucose tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Acromegaly</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

